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Abstract
Background: Clinical practice guidelines recommend colonoscopies at regular intervals for colorectal cancer (CRC)
survivors. Using data from a large, multi-regional, population-based cohort, we describe the rate of surveillance
colonoscopy and its association with geographic, sociodemographic, clinical, and health services characteristics.
Methods: We studied CRC survivors enrolled in the Cancer Care Outcomes Research and Surveillance (CanCORS)
study. Eligible survivors were diagnosed between 2003 and 2005, had curative surgery for CRC, and were alive
without recurrences 14 months after surgery with curative intent. Data came from patient interviews and medical
record abstraction. We used a multivariate logit model to identify predictors of colonoscopy use.
Results: Despite guidelines recommending surveillance, only 49% of the 1423 eligible survivors received a
colonoscopy within 14 months after surgery. We observed large regional differences (38% to 57%) across regions.
Survivors who received screening colonoscopy were more likely to: have colon cancer than rectal cancer
(OR = 1.41, 95% CI: 1.05-1.90); have visited a primary care physician (OR = 1.44, 95% CI: 1.14-1.82); and received
adjuvant chemotherapy (OR = 1.75, 95% CI: 1.27-2.41). Compared to survivors with no comorbidities, survivors with
moderate or severe comorbidities were less likely to receive surveillance colonoscopy (OR = 0.69, 95% CI: 0.49-0.98
and OR = 0.44, 95% CI: 0.29-0.66, respectively).
Conclusions: Despite guidelines, more than half of CRC survivors did not receive surveillance colonoscopy within
14 months of surgery, with substantial variation by site of care. The association of primary care visits and adjuvant
chemotherapy use suggests that access to care following surgery affects cancer surveillance.
Background
Colorectal cancer (CRC) survivors need ongoing preven-
tive care even after their cancer treatment is complete.
Because CRC survivors are at risk for both local recur-
rences and second primary cancers[1], clinical practice
guidelines from several gastroenterological and oncolo-
gical societies have long recommended routine surveil-
lance colonoscopy for survivors who have been treated
for cure[2-11]. By detecting second colorectal cancers
and local recurrences early enough to treat, surveillance
colonoscopy may increase treatment options and
decrease mortality. Until recently, multiple guidelines
offered conflicting recommendations for the timing of,
and interval between, surveillance colonoscopies[2-10].
(Table 1) In 2006, the American Cancer Society and U.
S. Multi-Society Task Force on Colorectal Cancer
recommended ongoing colorectal surveillance for people
with CRC via colonoscopy at 1 year after surgery, again
at 3 years and, if normal, every 5 years thereafter[11].
Unfortunately, many survivors do not receive their
first surveillance colonoscopy within 1 year after surgery,
and some never undergo surveillance. Estimates of CRC
survivors’ receipt of colon exams (including colonosco-
pies) range from 52-61% within 18 months of diagnosis
[12-16], 60-76% within 3 years[12,16-18], and only 51-
80% within 5 years[12,14,17,19]. Of more concern,
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however, are differences in routine surveillance by survi-
vor characteristics. Studies have suggested that factors
such as race and ethnicity, age, marital status, income,
geographic region, site of the tumor, comorbidities, and
stage may be associated with whether survivors undergo
appropriate surveillance[12-21].
Prior studies, however, have three important limita-
tions. First, they used data from 1986 through 2004
[12-21], a time period that does not reflect newer treat-
ment options. Second, these studies have included only
patients from restricted age and insurance groups (e.g.,
Medicare recipients), clinic-based populations, or regio-
nal health systems[12-18,21]. Finally, previous studies
have been limited to administrative data [12,13,
16,17,20,21], which may not capture important details
about survivors’ clinical characteristics.
We used interview and medical record data from a
recent nationwide population-based sample of CRC sur-
vivors to examine surveillance colonoscopy use. Specifi-
cally, we sought to: (1) estimate the rate of surveillance
colonoscopy use among CRC survivors 14 months after
surgery and (2) identify characteristics of survivors who
received colonoscopy in that time period.
Methods
Study sample
We studied participants in the Cancer Care Outcomes
Research and Surveillance (CanCORS) Consortium, a
multi-regional U.S. population-based cohort study of
lung and colorectal cancer. Detailed descriptions of Can-
CORS have been published elsewhere[22,23]. Briefly,
patients diagnosed with CRC or lung cancer were iden-
tified an average of 1.8 months after diagnosis from 4
geographic regions (Northern California, Los Angeles,
Alabama, and North Carolina); 15 Veterans Affairs (VA)
Medical Centers; and 5 members of the Cancer
Research Network, a network of managed care organiza-
tions designated by the National Cancer Institute to
conduct research on cancer prevention and control[24].
Because colonoscopy records in the Northern California
site and one of the managed care organizations were
incomplete, those data were not included in this analysis
(N = 944). CRC patients in CanCORS were diagnosed
from May 2003 through October 2005. The research
was approved by the Institutional Review Boards at each
site and all subjects gave written informed consent.
Inclusion and exclusion criteria
We restricted analyses to survivors who: (1) had stage I,
II, or III CRC; (2) received surgery within one month of
diagnosis (so that they had at least 14 months of follow-
up time), (3) were alive 14 months after surgery (so that
they had the opportunity to receive colonoscopy); and
(4) had adequate medical record data. Participants who
had local recurrences within the study period were
excluded, unless the recurrence was preceded (and
therefore possibly diagnosed) by a colonoscopy. Partici-
pants who had colonoscopies performed within 60 days
after surgery were excluded because it is likely that this
was due to complications form the initial surgery, was
prompted by symptoms, or was conducted in place of a
preoperative colonoscopy.
Data sources
Data for this study came from two sources. First, for eli-
gible participants providing informed consent, staff
trained by a central CanCORS team conducted medical
record audits, with quality control mechanisms in place.
Data on cancer-related medical visits and procedures
were extracted beginning 3 months before diagnosis
through 15 months after diagnosis. Second, interviews
with participants or their proxies (in the case of survivor
illness) were conducted approximately 4 months after
diagnosis. Interviews elicited information about symp-
toms, satisfaction with care, and other topics for which
survivors are an important source of information.
Table 1 Summary of guidelines for first routine surveillance colonoscopy among colorectal cancer survivors,
1999-2006
Year Recommending agency Timing of first colon exam
1999 American Society of Colon and Rectal Surgeons [3] Colonoscopy or barium enema 1-3 years post-surgery
2000 American Society of Clinical Oncology [2] Colonoscopy in 3-5 years
2003 American Cancer Society [4] Colonoscopy within 1 year post-surgery
2003 U.S. Multisociety Task Force on Colorectal Cancer Screening and Surveillance [5] Colonoscopy at 3 years post-surgery
2003 National Comprehensive Cancer Network [6] Colonoscopy within 3 years
2004 American Society of Colon and Rectal Surgeons [7] Colonoscopy in 1-3 years
2004 National Comprehensive Cancer Network [25] Colonoscopy within 3 years
2006 National Comprehensive Cancer Network [10] Colonoscopy in 1 year
2006 American Society for Gastrointestinal Endoscopy [32] Colonoscopy at 1 year post-surgery
2006 U.S. Multisociety Task Force on Colorectal Cancer Screening and Surveillance [11] Colonoscopy at 1 year post-surgery
Note: Table does not include recommendations for preoperative colonoscopies or those occurring postoperatively if preoperative colonoscopies are not possible.
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A centralized statistical and computing core derived key
variables, including staging, comorbidity, and adjuvant
treatment variables, from both abstracted medical
records and participant interviews.
Colonoscopy use
Our primary outcome was receipt of the first surveil-
lance colonoscopy within 14 months of surgery. While
some guidelines conflicted during the study period for
the timing of the first routine surveillance (i.e., 1 versus
3 years after surgery or diagnosis), we chose the 14-
month period, because 6 guidelines recommended a
colonoscopy at 1 year [4,10,11] or said it would be
appropriate[3,6,25]. In addition, the 14-month period
allowed us to balance the time allowed for survivors to
have surgery with adequate post-surgical follow-up ana-
lysis time within the available 15 months of post-diagno-
sis data.
Covariates
Sociodemographic data included age (from medical
records) and sex, race and ethnicity, income, insurance,
marital status, and education (from interviews). Clinical
data (predominantly from medical records) included site
of the tumor, stage at diagnosis, presence and severity
of comorbidities, cancer treatments, and visits to pri-
mary care physicians and medical oncologists. Staging
was determined using collaborative staging, or if it was
unavailable, from the best available data from the regis-
try, medical records, or interviews. Comorbidity was
assigned as none, mild, moderate, or severe using the
Adult Comorbidity Evaluation (ACE-27) index[26-28].
Adjuvant treatment was defined as having had che-
motherapy or radiation therapy within 6 months after
surgery.
Data analyses
Missing data were imputed using an iterative multivari-
able regression technique in Stata[29]. Analyses
excluded dichotomous predictor variables that had less
than 5% of the sample in one category. We used logistic
regression to examine bivariate and multivariate rela-
tionships between survivor characteristics (clinical and
demographic) and receipt of colonoscopy, using robust
standard errors corrected for heteroskedasticity. We cal-
culated odds ratios for the effect of each predictor on
colonoscopy use and conducted Wald c2 tests of joint
significance for categorical variables[30].
To describe the magnitude of the effect of dichoto-
mous predictors on the likelihood of colonoscopy use,
we computed average changes in predicted probability
using a multi-step process. For each variable of interest,
we subtracted the expected value of the dependent value
when the independent variable was equal to 0 from the
expected value of the dependent value when the inde-
pendent variable was equal to 1. The difference is the
average change in predicted probability resulting from
having the population change from the first (reference)
value of the predictor to the second (nonreference)
value. See Madden et al. for an example of this metho-
dology[31].
Results
Of 3,656 patients with newly-diagnosed CRC, 1,423
(39%) met all eligibility criteria and contributed data to
analyses (Figure 1). Thirty-five participants (2%) did not
complete interviews, and their interview data were
imputed. Most survivors (79%) had a primary colon, as
opposed to rectal, cancer. Demographic and clinical
characteristics of the cohort appear in Table 2. Because
of small cell sizes, we collapsed Asian, American Indian,
Pacific Islander, mixed race, other race, and unknown
race into a single category. Insurance status (i.e.,
whether participants had insurance), having had adju-
vant radiation, and speaking English were excluded from
regression analyses because of minimal variation in
these variables.
Only 49% of patients across all sites had a colono-
scopy within 14 months after surgery. In bivariate ana-
lyses, colonoscopy use varied by severity of
comorbidities, age, income, site of care, seeing a medical
oncologist, and having adjuvant chemotherapy. (Table 3)
In multivariate analysis (Table 3), the likelihood of
receiving surveillance colonoscopy was greater among
colon cancer than rectal cancer survivors (OR = 1.41,
95% CI: 1.05-1.90). Compared to survivors with no
comorbidities, survivors with moderate or severe comor-
bidities were less likely to receive surveillance colono-
scopy (OR = 0.69, 95% CI: 0.49-0.98 and OR = 0.44,
95% CI: 0.29-0.66, respectively). Those diagnosed at
stage III were less likely to receive surveillance colono-
scopy than those diagnosed at stage I (OR = 0.68, 95%
CI: 0.47-0.98), although the stage variables were not
jointly significant. Having seen a primary care provider
in the first year after diagnosis (OR = 1.44, 95% CI 1.14-
1.82) and having had adjuvant chemotherapy (OR =
1.75, 95% CI: 1.27-2.41) were both positively associated
with colonoscopy use.
Sites of care were strongly associated with colono-
scopy use. Compared to survivors enrolled through
managed care organizations in the Cancer Research
Network, survivors in North Carolina were more likely
to receive colonoscopy (OR = 2.32, 95% CI: 1.65-3.27),
as were survivors in Los Angeles (OR = 1.49, 95% CI:
1.03-2.15) and Alabama (OR = 1.92, 95% CI: 1.31-2.81).
There was no significant difference between rates of sur-
veillance colonoscopy in the VA sites and the managed
care organizations.
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The magnitude of the statistically significant dichoto-
mous predictors was calculated as an average marginal
effect, indicating the change in probability of receiving a
colonoscopy if every study participant first had the
reference value of an independent variable and then
changed to the indicator value. Assuming the relation-
ship between these factors and colonoscopy use is cau-
sal, if every participant in the study changed from not
seeing a primary care provider to seeing a primary care
provider, the likelihood of receiving a colonoscopy
would increase by 8 percentage points on average. Simi-
larly, a change from not having adjuvant chemotherapy
to having adjuvant chemotherapy would increase the
likelihood of receiving a colonoscopy by 13 percentage
points, on average.
Discussion
Guidelines recommend that CRC survivors receive regu-
lar surveillance via colonoscopy[2-7,10,11,25,32]. Pre-
vious studies found that the rate of surveillance
colonoscopy among CRC survivors is low; however,
these studies used older data sets which limit generaliz-
ability[12-15,17,19,21,33]. Using rich medical record and
interview data from a recent multi-regional population-
based cohort of CRC survivors, we extended prior
research on surveillance colonoscopy among CRC survi-
vors. This study using medical record abstraction
included survivors with a range of insurance types, ages,
and ethnic backgrounds, strengthening inferences about
external validity based on study findings.
We found that only 49% of CRC survivors received
surveillance colonoscopy. This rate is somewhat lower
than previously-reported rates at 18 months (52-61%)
[12-15]. The prior studies’ slightly higher estimates may
simply be due to additional analysis time or inclusion of
other colon examinations (such as sigmoidoscopy and
barium enema)[12-15]. However, given that colonosco-
pies were 70-97% [12-14] of all colon examinations, the
use of other examinations does not fully account for the
higher utilization rate in earlier studies. Cooper and
Payes[16] suggested that survivors may be delaying their
first colonoscopy until after 1 year. It is possible that
since 2002, the average time of receipt of the first post-
operative colonoscopy has become further delayed
beyond 14 months. Notably, sensitivity analyses sug-
gested that are findings are robust with respect to length
of post-surgical follow-up duration (13 months, 13.5
months, 14.5 months, and greater than 15 months after
diagnosis). Moreover, excluding patients with both rectal
and colon cancer (versus only one of the two) yielded
identical results for both the direction and statistical sig-
nificance of effect sizes.
There is large variation in surveillance colonoscopy
among subpopulations. The greatest variation was found
between study sites, where we found rates ranging from
37% to 57%. This finding is similar to the geographic
variation reported using Surveillance Epidemiology and
End Results (SEER) data and in a Canadian registry
study[18,19,21,33]. This regional variation may be a
function of differences in practice patterns or health
Inception medical record cohort
3656 patients with newly diagnosed CRC
324 missing surgery or stage data
373 stage IV
424 had surgery > 1 month after diagnosis (censored) 
122 died within 14 months after surgery
38 had colonoscopy within 60 days after surgery
8 recurred (not after colonoscopy)
1423 survivors
944 incomplete colonoscopy data (from 2 sites)
Figure 1 Flow diagram of study participants
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Table 2 Characteristics of study sample (N = 1423)
N %
Age
Less than 65 years 621 44
65 years and older 802 56
Annual income
<$50,000 592 42
≥ $50,000 460 32
Site of disease
Colon 1122 79
Rectum 259 18
Stage
I 413 29
II 499 35
III 505 35
Comorbidities
None 356 25
Mild 638 45
Moderate 256 18
Severe 173 12
Sex
Male 833 56
Female 590 41
Marital status
Married 792 56
Not married 580 41
Education
Less than high school 682 48
High school or more 687 48
Race/ethnicity
Non-Hispanic White 957 67
Non-Hispanic Black 257 18
Hispanic 84 6
Other 123 9
Site of care
Alabama 306 22
Los Angeles 300 21
North Carolina 416 29
VA hospitals 166 12
Managed care 235 17
Insurance
Insured 1232 87
Not insured 25 2
Speaks English
Yes 1386 97
No 29 2
Saw a primary care provider
Yes 868 61
No 553 39
Saw a medical oncologist
Yes 1032 73
No 391 27
Had adjuvant chemotherapy
Yes 590 41
No 833 59
Note: Percentages may not add to 100 because of missing data.
Table 3 Relationships between patient characteristics and
colonoscopy use within 14 months of surgery (N = 1423)
Had
colonoscopy
N (%)
Bivariate Multivariate
OR p OR p
All 692 (49)
Age
<65 years 328 (53) 1.35 <0.01 1.05 0.69
≥65 years 364 (45) 1.00 - 1.00 -
Sex
Male 393 (47) 0.87 0.19 0.87 0.26
Female 299 (51) 1.00 - 1.00 -
Site of tumor
Colon 576 (50) 1.28 0.08 1.41 0.02
Rectum 116 (44) 1.00 - 1.00 -
Stage
I 192 (46) 1.00 - 1.00 -
II 244 (49) 1.01 0.92 0.89 0.44
III 255 (50) 1.12 0.30 0.68 0.04
Comorbidities
None 197 (55) 1.00 - 1.00 -
Mild 330 (52) 1.25 0.04 0.92 0.56
Moderate 110 (43) 0.76 0.046 0.69 0.04
Severe 55 (32) 0.45 <0.01 0.44 <0.01
Race/ethnicity
Non-Hispanic
White
468 (49) 1.00 - 1.00 -
Non-Hispanic
Black
120 (47) 0.91 0.48 0.89 0.48
Hispanic 38 (45) 0.87 0.54 0.95 0.83
Other 66 (54) 1.25 0.24 1.50 0.05
Education
<high school 328 (46) 1.00 - 1.00 -
≥High school 364 (51) 1.22 0.07 1.07 0.62
Annual income
<$50,000 364 (44) 0.66 <0.01 0.74 0.05
≥$50,000 328 (55) 1.00 - 1.00 -
Marital status
Married 415 (51) 1.20 0.09 1.03 0.79
Not married 277 (46) 1.00 - 1.00 -
Site of care
Alabama 156 (51) 1.13 0.35 1.92 <0.01
Los Angeles 144 (48) 0.97 0.81 1.49 0.03
North Carolina 236 (57) 1.58 0.00 2.32 <0.01
VA hospitals 66 (40) 0.67 0.02 1.38 0.16
Managed care 90 (38) 1.00 - 1.00 -
Saw a primary care provider
Yes 440 (51) 1.22 0.06 1.44 <0.01
No 252 (46) 1.00 - 1.00 -
Saw a medical oncologist
Yes 530 (51) 1.49 <0.01 1.23 0.17
No 162 (41) 1.00 - 1.00 -
Had adjuvant chemotherapy
Yes 332 (56) 1.69 <0.01 1.75 <0.01
No 360 (43) 1.00 - 1.00 -
Note: OR = odds ratio.
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care delivery systems. Our results show that the utiliza-
tion of surveillance colonoscopy is lowest in managed
care organizations. Because the sites of care are either
geography-based, as in the Los Angeles and Alabama
sites, or based around a health care system, as in the
VA and the managed care sites, it is difficult to disen-
tangle these different possible influences on colonoscopy
use in the present study.
Clinical factors were strongly associated with colono-
scopy use. Rectal cancer survivors were less likely to
than those with colon cancer to receive colonoscopy,
which is consistent with previous reports[14,16,17,20].
Because colonoscopies comprised 96-99% of all proce-
dures performed, the higher use of sigmoidoscopy
among rectal patients is unlikely to account for this
finding[12,14,17]. Instead, less frequent colonoscopy use
among rectal cancer survivors may reflect a selection
bias. Rectal cancer survivors are more likely than colon
cancer survivors to get neoadjuvant therapy (chemother-
apy or radiation), but our criteria of surgery within one
month excluded many survivors who received neoadju-
vant therapy. Indeed, due to censoring, the proportion
of participants who received neoadjuvant therapy fell
from 9% to 1% among colon cancer survivors and from
30% to 0% among rectal cancer survivors. Because
patients who receive neoadjuvant therapy may be more
likely to have a timely colonoscopy, it is also possible
that those who were most likely to adhere to colono-
scopy guidelines were excluded from the analysis.
Survivors with more severe comorbidities were less
likely to receive a colonoscopy. Previous studies using
SEER data among Medicare fee-for-service populations
have shown similar findings[16,18,20], although two stu-
dies[14,15] of managed care populations showed no
effect of comorbidities on colonoscopy use. Patients
with more severe comorbidities may have shorter life
expectancies, leading physicians to be less likely to offer,
and patients less likely to accept, surveillance colono-
scopy. As well, survivors with more severe comorbidities
may be too frail to undergo colonoscopies.
Seeing a primary care physician in the first year after
diagnosis is associated with a higher likelihood of receiv-
ing a colonoscopy. Similarly, those individuals who
received adjuvant chemotherapy were more likely to
receive a colonoscopy. Two recent studies found that
CRC survivors who were seen by both an oncologist and
a primary care physician received the highest proportion
of recommended ongoing cancer preventive care (such as
cervical cancer screening and mammography) compared
to survivors who saw either type of physician (or had
seen neither)[34,35]. Primary care visits and chemother-
apy use may be indicators of access to high-quality care
and having a medical home, thereby increasing referral
for timely surveillance colonoscopies. If primary care
providers are responsible for most referrals, improving
coordination of care as patients move from acute cancer
care to ongoing care may increase adherence to colono-
scopy guidelines. The Institute of Medicine has priori-
tized facilitating this transition, with the goal of
improving ongoing care for cancer survivors[36].
Alternatively, prevention-oriented survivors may be
more likely to visit a primary care physician, to seek out
adjuvant chemotherapy to reduce the risk of recurrence,
and, similarly, to request a colonoscopy to reduce their
risk of cancer. Future longitudinal studies should
address survivors’ attitudes toward colonoscopy and
CRC prevention and whether these attitudes affect colo-
noscopy use.
Sociodemographic factors were not related to colono-
scopy use. Although previous studies have found asso-
ciations between sociodemographic factors and
colorectal surveillance, results have conflicted across
studies[12-18,20,21]. Taken together with the current
study, this suggests that sociodemographic factors are
inconsistent predictors of colonoscopy use. Instead, the
pattern of results appears to be that survivors are more
likely to undergo surveillance colonoscopy if they have
the best prognosis (those with mildest or no comorbid-
ities, earlier stage, and use of adjuvant chemotherapy) or
have a primary care physician.
This study has limitations. First, inclusion criteria of sur-
gery within 1 month after diagnosis could limit the find-
ings. However, sensitivity analyses that permitted longer
lags between diagnosis and surgery, as well as a sensitivity
analysis that did not limit timing of the surgery, showed
similar results. It is still possible that those with later sur-
geries and those with early post-surgical colonoscopies
had different patterns of colonoscopy use than their coun-
terparts. Second, this study sample was largely insured,
albeit to different extents and with different insurance
types. Despite high levels of insurance, however, differ-
ences in surveillance colonoscopy use were observed in
this study. Third, we were unable to assess the clinical
impact of nonadherence in our sample. Fourth, as we
could not assess reasons for colonoscopy use (i.e., diagnos-
tic versus surveillance), some colonoscopies may have
been diagnostic instead of for routine surveillance. This is
unlikely, though, because Cooper et al[37] looked at indi-
cations for colonoscopy use among cancer survivors and
found that 95% of colonoscopies performed were routine.
Fifth, the study assessed colonoscopy use by 14 months
after surgery. Although significant variations in colono-
scopy use were apparent even in this limited time frame, a
longer analysis period may have accommodated delays in
scheduling colonoscopies and revealed additional colonos-
copies that would still be adherent to clinical practice
guidelines in effect during the study period. A longer ana-
lysis period also would have included colonoscopies that
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were delayed due to long wait times. Finally, survivors who
were missing data on surgery and staging were excluded
from the analytic sample, and this may have created a
selection bias. Although we do not know whether those
with missing surgery data did not have colorectal cancer
surgery or whether their surgery data are missing, the
colonoscopy surveillance guidelines are targeted only to
patients who do have surgery. A subset of patients lacking
surgery data presumably did not have surgery and are
appropriately excluded from the analytic sample, limiting
the bias in our estimates. Patients who lacked staging
information had a 41% colonoscopy rate overall. The
lower rate of colonoscopies compared to the rate in the
analytic sample (49%) may simply reflect the presence of
patients with advanced disease in the unstaged sample;
patients with advanced disease are not appropriate candi-
dates for surveillance colonoscopy.
Conclusions
Despite guidelines, more than half of CRC survivors did
not receive surveillance colonoscopy within 14 months
of surgery, with substantial variation by site of care. The
association of primary care visits and adjuvant che-
motherapy use suggests that access to care following
surgery affects cancer surveillance. Future studies should
examine more closely the referral process for surveil-
lance colonoscopies in order to identify clinically inap-
propriate variation across subgroups of survivors.
Further clarifying which types of providers CRC cancer
survivors routinely see for follow up care, when these
visits occur, whether these physicians recommend colo-
noscopy consistent with existing guidelines, and whether
patients follow through with physicians’ recommenda-
tions to undergo colonoscopy is a first step. With the
often fragmented care of cancer survivors, it may be
unclear who is responsible for ensuring adherence to
colonoscopy guidelines. Oncologists, primary care provi-
ders, and other providers involved in the care of CRC
survivors must communicate with each other about
their separate responsibilities for detecting second pri-
mary cancers. To facilitate communication between pro-
viders, it is important to understand whether, as
recommended by the recent Institute of Medicine report
on cancer survivorship, cancer survivors are provided
with a survivorship care plan that includes a recommen-
dation for colonoscopy approximately one year following
treatment, whether cancer survivors share this informa-
tion with their primary care providers, and whether can-
cer survivors understand the information they receive
[36].
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